RESEARCH TRIANGLE PARK, NC, Nov. 5, 2020 — Pappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. (“VelosBio” or the...
Methylgene and Pharmion announce collaboration to develop sirtuin inhibitors as anti-cancer agents
News | 08. 20. 2007
MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today announced a research collaboration for the development of novel small molecule inhibitors targeting sirtuins, a separate and distinct class of histone deacetylase enzymes (Class 3 HDACs) implicated in cell survival and death.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.